SCHEMBL6380281

SCHEMBL6380281

O=C(N[C@H](C(=O)O)c1ccc(OCCn2ccc3ccccc32)cc1)c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.49
NPC1 O15118 3/20 0.49
RAB9A P51151 3/20 0.49
KMT2A Q03164 2/20 0.49
ALDH1A1 P00352 2/20 0.49
MEN1 O00255 1/20 0.49
MAPK1 P28482 1/20 0.47
PPARG P37231 2/20 0.46
FFAR1 O14842 1/20 0.46
TRPV1 Q8NER1 1/20 0.46
MCL1 Q07820 3/20 0.45
TP53 P04637 1/20 0.44
HTT P42858 1/20 0.44
HSD17B10 Q99714 1/20 0.44
MAPT P10636 2/20 0.43
LMNA P02545 2/20 0.43
PKM P14618 1/20 0.43
TBXAS1 P24557 1/20 0.41
ATM Q13315 1/20 0.41
PPARD Q03181 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6380636 1.00 SMN1; SMN2 (0.49) SMN1; SMN2NPC1RAB9AKMT2AALDH1A1
SCHEMBL6379224 0.80 FFAR1 (0.51) SMN1; SMN2NPC1RAB9AKMT2AALDH1A1
SCHEMBL6380456 0.77 PPARG (0.57) SMN1; SMN2NPC1RAB9AKMT2AALDH1A1
SCHEMBL6380285 0.76 FFAR1 (0.50) SMN1; SMN2NPC1RAB9AKMT2AALDH1A1
SCHEMBL6379239 0.75 SMN1; SMN2 (0.60) SMN1; SMN2NPC1RAB9AKMT2AALDH1A1
SCHEMBL6536655 0.75 PPARG (0.55) SMN1; SMN2NPC1RAB9AKMT2AALDH1A1
SCHEMBL6382414 0.73 NPC1 (0.47) SMN1; SMN2NPC1RAB9AKMT2AALDH1A1
SCHEMBL6382425 0.73 NPC1 (0.47) SMN1; SMN2NPC1RAB9AKMT2AALDH1A1
SCHEMBL6382416 0.72 SMN1; SMN2 (0.46) SMN1; SMN2NPC1RAB9AKMT2AALDH1A1
SCHEMBL6382619 0.71 FFAR1 (0.51) SMN1; SMN2NPC1RAB9AKMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050032787-A1 Pheny (alkyl)carboxylic acid derivatives and dionic phenylalkylheterocyclic derivatives and their use as medicines with serum glucose and/or serum lipid lowering activity SIGMA-TAU INDUSTRIES FARMACEUTICHE RIUNITE S.P.A. (IT) 2005-02-10 US claimed
US-20050032787-A1 Pheny (alkyl)carboxylic acid derivatives and dionic phenylalkylheterocyclic derivatives and their use as medicines with serum glucose and/or serum lipid lowering activity SIGMA-TAU INDUSTRIES FARMACEUTICHE RIUNITE S.P.A. (IT) 2005-02-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050032787-A1 Pheny (alkyl)carboxylic acid derivatives and dionic phenylalkylheterocyclic derivatives and their use as medicines with serum glucose and/or serum lipid lowering activity LIPC, CPT1A, GPR119 SMN1; SMN2 4124/4885NPC1 312/4885RAB9A 1357/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.